Loading
A phase 1/2 trial of Lenvatinib and Doxorubicin in endometrial cancer, hepatocellular carcinoma and colorectal cancer, run by Eisai Inc., active and no longer recruiting.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor is a phase 1/2 interventional study registered as NCT04008797 by Eisai Inc., with 301 participants enrolled, started 2019-07-11 and due to reach its primary completion in 2027-03-31. Interventions recorded: E7386, Lenvatinib, Doxorubicin and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Doxorubicin, Endometrial cancer and the tag pipeline.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Shares Doxorubicin, Hepatocellular carcinoma and the tag pipeline.
Shares Doxorubicin, Hepatocellular carcinoma and the tag pipeline.
Shares Endometrial cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/